Themis Bioscience Overview

  • Founded
  • 2009
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 40
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $1.11B
Latest Deal Amount

Themis Bioscience General Information

Description

Themis Bioscience NV is an immunomodulation clinical-stage biopharmaceutical group that focuses on the development of products to protect against infectious diseases and for the treatment of cancer. The company has developed a vaccine platform and broad pipeline based on the advanced understanding of immune system mechanisms.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Primary Office
  • Muthgasse 11/2
  • Vienna, 1190
  • Austria
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Themis Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 19-Jun-2020 $1.11B 000.00 00.000 Completed Generating Revenue
11. Later Stage VC (Series D) 18-Sep-2019 000.00 000.00 Completed Generating Revenue
10. Grant 04-Jun-2019 000.00 000.00 Completed Generating Revenue
9. IPO 09-Nov-2018 0000 00000 Postponed Clinical Trials - Phase 2
8. Grant 06-Mar-2018 0000 000.00 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series C) 04-Jan-2018 000.00 000.00 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series B) 29-Nov-2016 000.00 000.00 Completed Clinical Trials - Phase 2
5. Secondary Transaction - Private 00.000 Completed Startup
4. Early Stage VC (Series A) 18-May-2011 $7.24M $8.61M Completed Startup
3. Grant 06-Jul-2010 $1.23M $1.37M Completed Startup
To view Themis Bioscience’s complete valuation and funding history, request access »

Themis Bioscience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Themis Bioscience NV is an immunomodulation clinical-stage biopharmaceutical group that focuses on the development of pr
Biotechnology
Vienna, Austria
40 As of 2020
000.00
0.000 0000-00-00
000000&0 000.00

0000000

t labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris
0000 000000000
Cambridge, MA
000
00.00 0000-00-00
00000000000 000

0000000

consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nu
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Themis Bioscience Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnTolRx Venture Capital-Backed Cambridge, MA 000 00000000000 000
0000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
00000 000000000000 Formerly VC-backed Watertown, MA 00 00.000 00000000 00.000
00000 000000000 Formerly VC-backed South San Francisco, CA 00 0000 000000&0 0000
0000000 0000000000 Venture Capital-Backed San Mateo, CA 00 00000 0000000000 0 00000
To view Themis Bioscience’s complete competitors history, request access »

Themis Bioscience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Themis Bioscience Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Adjuvant Capital Impact Investing Minority 000 0000 000000 0
Austria Wirtschaftsservice Venture Capital Minority 000 0000 000000 0
Coalition for Epidemic Preparedness Innovations Corporation 000 0000 000000 0
FFG Finanzierungs- und Factorings Corporation Minority 000 0000 000000 0
Farallon Capital Management Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »